EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Body mass, linear growth, and body composition before and after the introduction of elexacaftor/tezacaftor/ivacaftor among children and adults with cystic fibrosis

Karlen Bader-Larsen, Bibi Uhre Nielsen, Esben Henriksen, Thomas Bryrup, Christian Leo-Hansen, Inger Hee Mabuza Mathiesen, Daniel Faurholt-Jepsen, Tavs Qvist, Peter Oturai, Bente Langdahl, Majbritt Jeppesen, Hanne Vebert Olsen und 4 weitere

Clinical Nutrition · 2025

DOI: 10.1016/j.clnu.2025.09.008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Nutrition, 2025. Verfasst von Karlen Bader-Larsen und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark; The Danish Cystic Fibrosis Cohort, Denmark. …. Hauptthemen laut MEDLINE: Cystic Fibrosis, Body Composition, Aminophenols, Benzodioxoles. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vertex Pharmaceuticals Incorporated.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Weight gain after elexacaftor/tezacaftor/ivacaftor (ETI) initiation among people with cystic fibrosis (CF) has been widely reported. How these weight changes compare with pre-existing trends, how they compare with linear growth, if they persist over time, and how they affect body composition have yet to be investigated. We assessed changes in body mass, linear growth, and body composition after ETI initiation. METHODS: Anthropometric data from people with CF in the Danish CF Registry were collected from 5 years pre-ETI initiation to 2 years post. Linear mixed-effects models with linear splines were used to assess changes in body mass index (BMI) in adults, and in BMI-for-age z-score (BMZ) and height-for-age z-score (HAZ) in children. Fat and fat-free mass from dual-energy X-ray absorptiometry (DXA) were compared using paired t-tests in adults. RESULTS: We included 392 people with CF. Among 154 children, BMZ was stable 5 years pre-ETI. Mean (95%CI) BMZ increased from -0.22 (-0.37, -0.07) at ETI initiation to 0.24 (0.05, 0.43) 2 years later. BMZ increased at a continuously higher rate post-ETI initiation compared to pre-ETI. HAZ increased by 0.05 (0.01, 0.09) per year pre-ETI, then remained stable post-ETI initiation, with no change from ETI initiation (0.12 (-0.03, 0.26)) to 2 years post-ETI. Among 238 adults, BMI increased by 0.05 (0.004, 0.10) kg/m2 per year pre-ETI. BMI increased from 22.55 (22.08, 23.02) kg/m2 at ETI initiation to 23.75 (23.25, 24.25) kg/m2 after 2 years, but the annual rate of change returned to pre-ETI trends after 9 months. In a subset of 115 adults with available DXA data, mean fat mass index increased by 0.68 kg/m2 (0.01, 1.35) 1 year post-ETI initiation, with no significant gain of fat-free mass index. CONCLUSIONS: Children with CF continued to increase their BMZ 2 years post-ETI initiation, while HAZ remined stable. The rate of change in BMI returned to pre-ETI trends among adults with CF. Adult BMI gains were primarily driven by an increase of fat mass.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisBody CompositionAminophenolsBenzodioxolesQuinolonesIndolesPyridinesPyrrolidinesPyrazolesHumansMaleFemaleChildAdultBody Mass IndexDrug CombinationsAdolescentYoung AdultDenmarkWeight GainRegistriesQuinolines

Stichwörter der Autor:innen

Dual-energy X-ray absorptiometryFat massFat-free massHeightNutritionWeight

Substanzen

AminophenolsBenzodioxolesDrug CombinationsQuinolonesIndolesPyridinesPyrrolidinesPyrazoleselexacaftor, ivacaftor, tezacaftor drug combinationQuinolines

Autor:innen und Institutionen

  • Department of Infectious Diseases, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark; The Danish Cystic Fibrosis Cohort, Denmark. Electronic address: karlen.stade.bader.larsen@regionh.dk.
  • Department of Infectious Diseases, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark; The Danish Cystic Fibrosis Cohort, Denmark.
  • Department of Infectious Diseases, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; The Danish Cystic Fibrosis Cohort,…
  • Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
  • Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark; The Danish Cystic Fibrosis Cohort, Denmark.

Förderung

  • Vertex Pharmaceuticals Incorporated

Zitieren

APA

Bader-Larsen, K., Nielsen, B. U., Henriksen, E., Bryrup, T., Leo-Hansen, C., Mathiesen, I. H. M., Faurholt-Jepsen, D., Qvist, T., Oturai, P., Langdahl, B., Jeppesen, M., Olsen, H. V., Pressler, T., Skov, M., Olsen, M. F., & Transform CF Study Group (2025). Body mass, linear growth, and body composition before and after the introduction of elexacaftor/tezacaftor/ivacaftor among children and adults with cystic fibrosis. Clinical Nutrition. https://doi.org/10.1016/j.clnu.2025.09.008

Vancouver

Bader-Larsen K, Nielsen BU, Henriksen E, Bryrup T, Leo-Hansen C, Mathiesen IHM, et al. Body mass, linear growth, and body composition before and after the introduction of elexacaftor/tezacaftor/ivacaftor among children and adults with cystic fibrosis. Clinical Nutrition. 2025. doi:10.1016/j.clnu.2025.09.008

BibTeX
@article{BaderLarsen2025,
  author = {Bader-Larsen, Karlen and Nielsen, Bibi Uhre and Henriksen, Esben and Bryrup, Thomas and Leo-Hansen, Christian and Mathiesen, Inger Hee Mabuza and Faurholt-Jepsen, Daniel and Qvist, Tavs and Oturai, Peter and Langdahl, Bente and Jeppesen, Majbritt and Olsen, Hanne Vebert and Pressler, Tacjana and Skov, Marianne and Olsen, Mette Frahm and Transform CF Study Group, Transform CF Study Group},
  title = {Body mass, linear growth, and body composition before and after the introduction of elexacaftor/tezacaftor/ivacaftor among children and adults with cystic fibrosis},
  journal = {Clinical Nutrition},
  year = {2025},
  doi = {10.1016/j.clnu.2025.09.008}
}
Kostenlos starten →